Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Arkansas: below-average open trial sites
676 of 2,376 in-state trials are recruiting (28%); below the 37% national average by 9 percentage points, with Phase 3 weight.
According to ClinicalTrials.gov-derived indexes, Arkansas sits in the upper half of US states by in-state trial count (#24 of 52 states by registered in-state trial count).
Arkansas: 2,376 US clinical trials with in-state sites, 676 recruiting.
Arkansas has 2,376 registered US clinical trials with a study site in-state, 676 of them currently recruiting (below the 37% national average by 9 percentage points). 969 of these trials are in Phase 3 (late-stage) and 637 in Phase 2. The most frequently studied condition in Arkansas is Breast Cancer, with 53 linked trials.
Mid-pack research density
Arkansas sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Below-average open enrollment
Arkansas still shows 676 recruiting of 2,376 in-state trials (28% open), but below the 37% national average by 9 percentage points, so archived statuses weigh heavier than the national baseline.
- 28%
- open (below national share)
- 676
- still recruiting despite cool share
- 637
- Phase 2 rows in this footprint
- 53
- top: Breast Cancer
Recruiting share is below the 37% national average by 9 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Arkansas vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
2,376 Top 46% more indexed trials than 54% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Arkansas on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Arkansas open-enrollment share sits below the national baseline.
676 of 2,376 in-state trials (28.5%) are recruiting, against 37% nationally (-8.5 percentage points). Counts include every study with at least one recorded site in the state.
-
Little Rock dominates Arkansas's trial geography.
Little Rock lists 1,591 of 2,376 in-state trials (67%) across 473 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in Arkansas.
53 of 2,376 in-state trials (2.2%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
Arkansas sponsorship is fragmented across many organizations.
National Cancer Institute (NCI) appears on 174 of 2,376 in-state trials (7.3%). Sponsor identity is as filed on ClinicalTrials.gov.
-
1,075 Arkansas trials carry a completed status.
1,075 of 2,376 (45.2%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 1,075 |
| Recruiting | 676 |
| Active | 625 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 3 | 969 |
| Phase 2 | 637 |
| NA | 267 |
| Phase 1 | 159 |
| Phase 4 | 105 |
| Early Phase 1 | 2 |
Top Conditions
Top Sponsors
Where trials run in Arkansas
Little Rock carries 1,591 of Arkansas's 2,376 indexed trials (67%) across 473 named sites, ahead of Jonesboro at 296. 8 cities clear five listed trials, together naming 882 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Little Rock | 1,591 | 473 |
| Jonesboro | 296 | 98 |
| Hot Springs | 253 | 70 |
| Fort Smith | 236 | 37 |
| Fayetteville | 173 | 60 |
| Springdale | 140 | 50 |
| Rogers | 130 | 55 |
| North Little Rock | 79 | 39 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share low
Arkansas open-enrollment share is 28% (p18 of states with sites; national baseline 37%).
Arkansas: open share sits in the low tercile of states
Geography is concentrated: Little Rock alone accounts for 67% of Arkansas's indexed trials (1,591 of 2,376), with Jonesboro a distant second at 296.
Phase mix: 969 Phase 3 vs 637 Phase 2 (later-stage heavy).
Top condition: Breast Cancer (53 trials); top sponsor National Cancer Institute (NCI) (174).
mid-volume · low-open figures (2,376 trials · 28% open) describe registry geography under the open-share low read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Arkansas on open-enrollment share
Cross-state peers under the open-share low read (mid-volume · low-open), not the same-state browse list.
Similar mid-volume peers (± open share)
- District of Columbia · 2,316 trials · 31% recruiting
- Kentucky · 2,183 trials · 32% recruiting
- Virginia · 2,598 trials · 40% recruiting
- Oregon · 1,999 trials · 34% recruiting
- Washington · 2,795 trials · 33% recruiting
Similar low-open peers (± trial volume)
- Alabama · 29% recruiting · 4,168 trials
- Indiana · 29% recruiting · 3,113 trials
- New Mexico · 29% recruiting · 579 trials
- Kansas · 29% recruiting · 2,080 trials
- Louisiana · 28% recruiting · 1,936 trials